CADTH is pleased to announce the election of 3 new members to the CADTH Board of Directors.
“On behalf of the Board, I am pleased to welcome Louise Taylor Green, Dr. Jeffrey Tyberg, and Robert Shaffer as directors," said David Agnew, Board Chair. "Each of these remarkable individuals brings unique expertise, experience, and perspective to the board and we are delighted that they’ve joined us."
The international collaboration between 6 health technology assessment (HTA) bodies from across the UK, Australia, and Canada welcomes 2 further HTA bodies.
The addition of the Institut national d’excellence en santé et en services sociaux (INESSS) (Quebec) and Pharmac (New Zealand) to the collaboration will see more than 134 million people benefit from the group’s work.
The group, established in 2021, now includes:
CADTH is establishing an industry task force that will build upon the recently released Guidance for Reporting Real-World Evidence to provide advice on the use of industry-generated real-world data (RWD) in its Post-Market Drug Evaluation (PMDE) Program. We are inviting industry representatives to apply to be a part of this task force.
A message from Suzanne McGurn, President and CEO, CADTH
On behalf of CADTH and our Board of Directors, I’m pleased to share the CADTH Annual Report for 2022–2023.
The theme of this year’s report, Ahead of the Curve, aligns with our strategic plan and our efforts to shape a future-ready health system in Canada.